The present study was designed (a) to characterize the activity of loxiglumide as a peripheral cholecystokinin (CCK) antagonist in healthy human subjects, and (b) to determine whether CCK is a physiologic regulator of the intestinal phase of meal-stimulated exocrine pancreatic and biliary secretions in man. Intravenous loxiglumide (22 mumol/kg per h) was highly potent in antagonizing CCK8-induced pancreatic enzyme and bile acid secretion as well as pancreatic polypeptide release. The potency and selectivity of loxiglumide as an antagonist of CCK provides the tool for evaluating the role of CCK as a physiological mediator of meal-induced pancreatic and biliary responses in humans. Infusion of a liquid test meal into the duodenum evoked an immediate response of pancreatic enzyme and bilirubin outputs, respectively. Intravenous loxiglumide significantly inhibited the meal-induced pancreatic amylase output by 63% (P less than 0.05), lipase output by 43% (P less than 0.05), and bilirubin output by 59% (P less than 0.05). These data suggest that CCK is a physiological mediator of the intestinal phase of meal-stimulated pancreatic and biliary responses. 
Introduction
Despite a large number ofphysiological studies on meal-stimulated pancreatic enzyme secretion in man, many crucial questions remain unanswered. For example, the physiological role of cholecystokinin (CCK),' one of the classical intestinal hormones, has remained controversial (1'-3 ). There appears to be no doubt that plasma CCK increases after a meal. Also, by comparing increments in plasma CCK and pancreatic trypsin secretion after a meal and after exogenous CCK, we have previously suggested that CCK could be a major stimulatory mechanism of postprandial pancreatic trypsin secretion (4) . The availability of potent antagonists of CCK binding to its membrane receptor enabled us to reexamine the role of CCK peptide.
as a regulator of pancreatic and biliary secretion in man (5) (6) (7) (8) (9) (10) (11) (12) . The results support the concept that CCK is a major stimulatory mechanism of intestinal phase-stimulated pancreatic enzyme and biliary responses.
Methods
Subjects. 12 healthy male volunteers aged 22-28 yr (mean, 24 yr) whose bodyweight was within 10% of their ideal value (mean, 72 kg) participated in the studies. None was taking any medication or had any history of gastrointestinal or endocrine symptoms and surgery. The studies were approved by the University of Basel Human Ethical Committee on 14 July 1987 , and written informed consent was obtained from each subject.
Experimental procedure. Subjects were studied after an overnight fast. The order of experiments was randomized. Pancreatic and biliary secretions were studied with the standard gastroduodenal intubation marker peqfusion technique detailed elsewhere (4) . In brief, a fourlumen tube was placed under fluoroscopic guidance. The gastric aspiration site was situated in the antrum for continuous gastric aspiration. Normal saline containing polyethylene glycol (PEG4000) as a nonabsorbable marker was instilled into the second portion ofthe duodenum in a concentration of 2 g/liter and at 2 ml/min. The duodenal contents were recovered in 15-min aliquots at the distal aspiration site near the ligamentum of Treitz.
Pharmacological characterization ofloxiglumide. In this part ofthe study, secretin was infused intravenously for the duration of each experiment at a rate of 16.4 pmol/kg per h. After a 75-min period with secretin alone, doubling doses of CCK8 (4.7-37 pmol/kg per h) were infused intravenously, each dose for 45 min. These doses have previously been'shown to produce threshold to maximal pancreatic enzyme secretion (13, 14) . In three subjects, an additional dose ofCCK8 (72 pmol/kg per h) was given to test whether the inhibitory effect of loxiglumide is surmountable with supramaximal'doses of CCK8. On different days and in random order, either saline (control) or two different doses ofloxiglumide (3.3 or 10 mg/kg per h equal to 7 and 22 ;imol/kg per h), dissolved in 0.9% saline, were infused through an indwelling catheter in a forearm vein for the duration of the experiments (255 min).
Plasma samples were obtained in regular intervals before stimulation and during the last 15 min of each dose of CCK8. Blood was collected in ice-chilled EDTA tubes containing 5,000 kallikrein-inhibiting units aprotinin/5 ml blood. Samples were immediately centrifuged at 4VC and the plasma stored at -20'C until assayed for CCK, pancreatic polypeptide (PP), and loxiglumide plasma concentrations.
To evaluate the specificity of loxiglumide, dose-response curves were performed in five subjects with graded doses of secretin (5 and 15 pmol/kg per h) and bombesin (1-27 pmol/kg per h) given with concomitant infusions ofloxiglumide (22 Atmol/kg per h) or, alternatively, saline (control). Pancreatic and biliary secretions were collected as described above. Each dose of each stimulant was given for 45 min.
To further test the specificity of loxiglumide as a CCK antagonist against a structurally related substance such as gastrin, the effect ofthe compound on pentagastrin-stimulated acid secretion was studied in four healthy subjects. After a 45-min basal period, pentagastrin was given in graded doses (65, 260, and 1,042 pmol/kg per h), each given for 45 min. The experiments were repeated with loxiglumide (22 Amol/kg per h). Gastric acid secretion was measured by continuous aspiration using a double-lumen gastric tube and marker perfusion technique (PEG4000) (13) .
Meal studies. After proper placement of the intestinal four-lumen tube, indwelling catheters were inserted into both cubital veins for blood sampling and infusion, respectively. After a 60-min basal period with saline perfusion to the duodenum, a liquid test meal was perfused into the duodenum for 120 min at the rate of 2 ml/min. This perfusion rate was used to simulate the rate of gastric emptying of a liquid test meal (7) . The (19) , and PEG turbidimetrically (20) . The duodenal fluid secretion for a given period was calculated as described previously (4) . The recovery of the duodenal marker averaged 87±3% (mean±SEM), whereas the average percentage of PEG recovered from the stomach was < 2%. Recoveries were similar in the different experiments and were unaffected by loxiglumide administration. Gastric fluid was measured to the next milliliter; acid concentration was determined by titration, and PEG concentration was measured turbidimetrically (20) .
Assays. Plasma CCK concentrations were estimated as previously described (21) and all measurements were done with antibody T204. This antibody has been extensively characterized (22) and has been shown to bind to all carboxyl-terminal CCK peptides containing the sulfated tyrosine. The antibody shows < 2% crossreactivity to sulfated gastrins and does not bind to unsulfated forms ofgastrin or structurally unrelated peptides. Furthermore, loxiglumide does not interfere with the assay. The sensitivity of the assay was 0.5 pmol/liter plasma. The intraassay variation was < 10% at 2.6 pmol/liter. All samples were assayed in the same run.
Coded plasma samples were assayed for PP concentration using previously described methods (23) . The sensitivity of the assay was 2 pmol/liter plasma.
Loxiglumide concentrations were measured by HPLC according to methods described elsewhere (24 sponses to CCK8 produced by the higher dose of loxiglumide was essentially complete. Both doses of loxiglumide completely antagonized the potentiating effect of CCK8 on the bicarbonate response to secretin (Fig. 1) ; In the three subjects who received an additional dose of CCK8 (72 pmol/kg per h), we observed a diminished inhibition of pancreatic enzyme output during the lower dose ofloxiglumide (7 pmol/kg per h), suggesting that the inhibition caused by loxiglumide was surmountable. CCK8-induced bile acid secretion. Basal bile acid output was very low and not affected by loxiglumide.
Step-doses of CCK8 induced increasing bile acid output with a maximal response obtained at a dose of 9.2 pmol/kg per h (Fig. 2) . Both doses of loxiglumide completely blocked CCK8-stimulated bile acid secretion (P < 0.01). Secretin-stimulated secretion. During infusion of saline (control), mean fasting pancreatic secretion was constant. The infusion of loxiglumide for 75 min caused a marked decrease in enzyme output, but had no significant effect on fluid and bicarbonate secretion (Fig. 3) . Graded doses of secretin induced a dose-dependent increase in fluid and bicarbonate secretion, which was not affected by loxiglumide (Fig. 4) .
Bombesin-stimulated secretion. Bombesin (1-27 pmol/kg per h) stimulated pancreatic enzyme and bicarbonate secretion in a dose-dependent manner (Fig. 5) . A dose of22 ,umol/kg per h of loxiglumide did not affect this response. CCK8-induced PP release. CCK8 caused a dose-dependent increase in plasma PP over basal concentrations (Table II) . Loxiglumide produced a complete antagonization of the PP response to CCK8 (P < 0.01).
Acid responses to pentagastrin with and without loxiglumide. Intravenous pentagastrin resulted in a dose-related significant increase in gastric acid output. The administration' of 22 ,umol/kg per h loxiglumide did not significantly change the acid response to pentagastrin (Fig. 6) .
Plasma CCK concentrations. Fasting plasma CCK levels were comparable in the different experiments. Increasing doses of CCK8 produced a dose-dependent increase in plasma CCK-like immunoreactivity, which was significant for the lowest dose already (Table II) 59% (Table III , P < 0.05). Fluid secretion during meal perfusion reached 308±65 ml/120 min in control experiments and was not significantly different with the antagonist (379±127 ml/ 120 min). Plasma CCK concentrations. Fasting plasma CCK levels were 1.8±0.1 pmol/liter for experiments both with and without loxiglumide. Perfusion of the meal into the duodenum evoked a prompt and significant increase of plasma CCK concentrations. Loxiglumide significantly augmented the CCK response to intraduodenal meal stimulation (AUC with loxiglumide was roughly four times higher compared with control; P < 0.05) (Fig. 8) .
Plasma PP concentrations. Loxiglumide did not affect unstimulated plasma PP concentrations. Duodenal perfusion of the test meal caused a significant increase in PP response (AUC = 4,431±1,583 pM-120 min, P < 0.05) during saline perfusion. Loxiglumide completely suppressed (P < 0.05) this response (AUC = 614±582, P < 0.05).
Discussion
Loxiglumide has been characterized as a new potent antagonist of CCK (8) (9) (10) (11) (12) . In vitro studies have demonstrated higher affinity of loxiglumide for peripheral CCK receptors than for brain CCK receptors and competitive antagonization of CCK8-stimulated gallbladder contraction, pancreatic enzyme release, and smooth muscle strip contractions (8-1 1 The present study shows that a significant increase in plasma CCK is found after perfusion of a test meal to the duodenum, confirming several previous reports with oral food intake (4, (27) (28) (29) . The magnitude of the postprandial CCK release amounted to 2-3 pmol/liter, which is in the same range previously reported for oral meals (4, (27) (28) (29) Pronounced inhibitory effects have been described after atropine administration or vagotomy on exocrine pancreatic secretory responses, but not on plasma CCK release, suggesting a major role for direct cholinergic stimulation ofpancreatic enzyme secretion during meal stimulation (30) . The present data are not a contradiction to these observations, but are compatible with these latter results: a sustained secretory response remained after administration of the CCK antagonist loxiglumide, although all endogenous CCK should have been blocked in the study by loxiglumide. We take the residual pancreatic secretory response in response to intestinal meal stimulation observed in the blocker experiment as evidence for the existence of other stimulatory mechanisms such as cholinergic stimulation.
This study revealed that plasma CCK levels were increased three-to fourfold in the meal experiment with concomitant loxiglumide administration. Owyang and co-workers have shown that CCK release is regulated by intraduodenal trypsin, suggesting that feedback control of pancreatic enzyme secretion is operative in man (30) . Thus, the reduced pancreatic enzyme response observed in the blocker experiment could induce stimulation of CCK through a positive feedback control.
The cholinergic mediation of PP release and its inhibition by atropine are well established (31, 32) . Here, we demonstrate that loxiglumide nearly abolished intestinal phase-stimulated plasma PP release. These findings extend the previous observations with atropine (31, 32) and suggest that both the cholinergic and the peptidergic (CCK) system are required for a regular PP response to intestinal phase stimulation.
Several questions remain unanswered in this study. What is the contribution of CCK to the cephalic and gastric phase of pancreatic secretion? Do other factors interact with CCK to augment its effect on pancreatic enzyme secretion during the various postprandial phases? Which molecular form ofCCK is predominant after meal stimulation? More information is clearly required to answer these questions.
In conclusion, the results of the present study support the concept that cholecystokinin plays a physiological role in the regulation ofthe intestinal phase ofhuman pancreatic enzyme and biliary secretions after meal stimulation. We conclude that CCK is an important gastrointestinal hormone in human digestive physiology.
